Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.4600 +0.0700 (+5.04%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.4600 unch (unch) 15:59 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3900
Day High
1.4692
Open 1.4100
Previous Close 1.3900 1.3900
Volume 19,100 19,100
Avg Vol 53,615 53,615
Stochastic %K 30.04% 30.04%
Weighted Alpha -60.85 -60.85
5-Day Change +0.0500 (+3.55%) +0.0500 (+3.55%)
52-Week Range 1.1500 - 4.4400 1.1500 - 4.4400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,407
  • Shares Outstanding, K 17,559
  • Annual Sales, $ 460 K
  • Annual Income, $ -5,800 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.86
  • Price/Sales 52.22
  • Price/Cash Flow N/A
  • Price/Book 3.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/25
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.15
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2800 +14.06%
on 04/07/25
Period Open: 1.7700
1.8955 -22.98%
on 03/24/25
-0.3100 (-17.51%)
since 03/21/25
3-Month
1.1500 +26.96%
on 03/04/25
Period Open: 1.9800
2.0268 -27.97%
on 01/23/25
-0.5200 (-26.26%)
since 01/22/25
52-Week
1.1500 +26.96%
on 03/04/25
Period Open: 2.2650
4.4400 -67.12%
on 06/03/24
-0.8050 (-35.54%)
since 04/22/24

Most Recent Stories

More News
Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Lexaria's Human GLP-1 Study #5 Begins Dosing

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria executing a triple-pronged strategy in obesity and diabetes

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Pursuing the world's first-ever orally-dosed liraglutide

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Additions broaden DehydraTECH patent suite for Epilepsy

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)
Lexaria Releases Annual Letter from the CEO

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide...

LEXXW : 0.3699 (+8.79%)
LEXX : 1.4600 (+5.04%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 1.5687
2nd Resistance Point 1.5189
1st Resistance Point 1.4895
Last Price 1.4600
1st Support Level 1.4103
2nd Support Level 1.3605
3rd Support Level 1.3311

See More

52-Week High 4.4400
Fibonacci 61.8% 3.1832
Fibonacci 50% 2.7950
Fibonacci 38.2% 2.4068
Last Price 1.4600
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro